A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma.

被引：3
|
作者：
Yau, C. C.
Chan, P.
Pang, R.
Chan, W.
Cheng, P. N.
Poon, R.
机构：
[1] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
[2] 813 Med Ctr Ltd, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e13503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13503
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I radioimmunotherapy trial of 131I-huA33 in patients with advanced colorectal carcinoma.
    Chong, G
    Lee, F
    Hopkins, W
    Mountain, A
    Potasz, N
    Murphy, R
    Chappell, B
    Schleyer, P
    Papenfus, T
    O'Keefe, GJ
    Cebon, PUJ
    Mitchell, P
    Poon, A
    Burgess, AW
    Hoffman, E
    Old, LJ
    Scott, AM
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 32P - 32P
  • [22] A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
    Thomas Yau
    P. N. Cheng
    Pierre Chan
    William Chan
    Li Chen
    Jimmy Yuen
    Roberta Pang
    S. T. Fan
    Ronnie T. Poon
    Investigational New Drugs, 2013, 31 : 99 - 107
  • [23] A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
    Yau, Thomas
    Cheng, P. N.
    Chan, Pierre
    Chan, William
    Chen, Li
    Yuen, Jimmy
    Pang, Roberta
    Fan, S. T.
    Poon, Ronnie T.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 99 - 107
  • [24] A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer
    Gunawardana, DH
    Basser, RL
    Davis, ID
    Cebon, J
    Mitchell, P
    Underhill, C
    Kilpatrick, TJ
    Reardon, K
    Green, MD
    Bardy, P
    Amor, P
    Crump, D
    Ng, S
    Nation, RL
    Begley, CG
    CLINICAL CANCER RESEARCH, 2003, 9 (06) : 2056 - 2065
  • [25] Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.
    Feun, Lynn G.
    Li, Ying-Ying
    Wangpaichitr, Medhi
    Jones, Patricia Denise
    Richman, Stephen P.
    Madrazo, Beatrice
    Kwon, Deukwoo
    Martin, Paul
    Hosein, Peter Joel
    Savaraj, Niramol
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Phase I/II study of CPT-11 plud CDDP in patients with advanced gastric carcinoma.
    Tanabe, S
    Kurihara, M
    Koizumi, W
    Satoh, A
    Takiuchi, H
    Akazawa, S
    Kudo, Y
    Fukuyama, Y
    Iwasaki, R
    Saigenji, K
    Shimada, K
    ANNALS OF ONCOLOGY, 2000, 11 : 64 - 64
  • [27] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Shuntaro Obi
    Shigetoshi Fujiyama
    Shuichiro Shiina
    Hideyuki Tamai
    Hitoshi Mochizuki
    Yukihiro Koike
    Jun Imamura
    Takayoshi Yamaguchi
    Isamu Saida
    Osamu Yokosuka
    Masao Omata
    Hepatology International, 2014, 8 : 94 - 103
  • [28] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Obi, Shuntaro
    Fujiyama, Shigetoshi
    Shiina, Shuichiro
    Tamai, Hideyuki
    Mochizuki, Hitoshi
    Koike, Yukihiro
    Imamura, Jun
    Yamaguchi, Takayoshi
    Saida, Isamu
    Yokosuka, Osamu
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103
  • [29] A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC)
    Okusaka, Takuji
    Ikeda, Masafumi
    Ohkawa, Shinichi
    Yamamoto, Shunsuke
    Suzuki, Ikue
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [30] A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma
    Yoshihiko Ooka
    Tetsuhiro Chiba
    Sadahisa Ogasawara
    Kuniaki Arai
    Eiichiro Suzuki
    Akinobu Tawada
    Tatsuya Yamashita
    Fumihiko Kanai
    Shuichi Kaneko
    Osamu Yokosuka
    Investigational New Drugs, 2014, 32 : 723 - 728
12345